Barclays’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-10,700
| Closed | -$1.85M | – | 5086 |
|
|
2021
Q4 | $1.85M | Hold |
10,700
| – | – | ﹤0.01% | 2435 |
|
|
2021
Q3 | $1.55M | Buy |
10,700
+10,000
| +1,429% | +$1.46M | ﹤0.01% | 2514 |
|
|
2021
Q2 | $92K | Hold |
700
| – | – | ﹤0.01% | 3873 |
|
|
2021
Q1 | $90K | Hold |
700
| – | – | ﹤0.01% | 4043 |
|
|
2020
Q4 | $83K | Sell |
700
-79,300
| -99% | -$9.67M | ﹤0.01% | 4207 |
|
|
2020
Q3 | $9.16M | Buy |
80,000
+47,900
| +149% | +$5.66M | 0.01% | 1067 |
|
|
2020
Q2 | $3.66M | Sell |
32,100
-9,100
| -22% | -$965K | ﹤0.01% | 1613 |
|
|
2020
Q1 | $3.31M | Buy |
41,200
+35,500
| +623% | +$3.68M | ﹤0.01% | 1835 |
|
|
2019
Q4 | $609K | Sell |
5,700
-25,500
| -82% | -$2.66M | ﹤0.01% | 4120 |
|
|
2019
Q3 | $3.34M | Buy |
31,200
+26,000
| +500% | +$2.67M | ﹤0.01% | 2270 |
|
|
2019
Q2 | $529K | Sell |
5,200
-2,900
| -36% | -$279K | ﹤0.01% | 4269 |
|
|
2019
Q1 | $728K | Sell |
8,100
-8,500
| -51% | -$737K | ﹤0.01% | 3751 |
|
|
2018
Q4 | $1.38M | Buy |
16,600
+11,300
| +213% | +$1.06M | ﹤0.01% | 2786 |
|
|
2018
Q3 | $572K | Sell |
5,300
-2,900
| -35% | -$318K | ﹤0.01% | 4164 |
|
|
2018
Q2 | $902K | Sell |
8,200
-1,000
| -11% | -$104K | ﹤0.01% | 3394 |
|
|
2018
Q1 | $923K | Sell |
9,200
-13,600
| -60% | -$1.39M | ﹤0.01% | 3311 |
|
|
2017
Q4 | $2.25M | Sell |
22,800
-7,400
| -25% | -$702K | ﹤0.01% | 2323 |
|
|
2017
Q3 | $2.83M | Buy |
30,200
+28,200
| +1,410% | +$2.99M | ﹤0.01% | 2014 |
|
|
2017
Q2 | $222K | Buy |
2,000
+1,000
| +100% | +$106K | ﹤0.01% | 4281 |
|
|
2017
Q1 | $98K | Sell |
1,000
-4,300
| -81% | -$410K | ﹤0.01% | 4887 |
|
|
2016
Q4 | $487K | Sell |
5,300
-900
| -15% | -$77.6K | ﹤0.01% | 3396 |
|
|
2016
Q3 | $525K | Hold |
6,200
| – | – | ﹤0.01% | 3181 |
|
|
2016
Q2 | $505K | Sell |
6,200
-5,700
| -48% | -$434K | ﹤0.01% | 3205 |
|
|
2016
Q1 | $845K | Sell |
11,900
-14,500
| -55% | -$972K | ﹤0.01% | 2672 |
|
|
2015
Q4 | $1.87M | Buy |
26,400
+4,900
| +23% | +$329K | ﹤0.01% | 2070 |
|
|
2015
Q3 | $1.31M | Buy |
21,500
+10,500
| +95% | +$734K | ﹤0.01% | 2477 |
|
|
2015
Q2 | $792K | Sell |
11,000
-43,500
| -80% | -$3.21M | ﹤0.01% | 3094 |
|
|
2015
Q1 | $4.14M | Sell |
54,500
-140,000
| -72% | -$10M | ﹤0.01% | 1713 |
|
|
2014
Q4 | $13M | Buy |
194,500
+143,700
| +283% | +$9.07M | 0.01% | 1011 |
|
|
2014
Q3 | $3.05M | Sell |
50,800
-181,800
| -78% | -$11.2M | ﹤0.01% | 2275 |
|
|
2014
Q2 | $13.5M | Buy |
232,600
+120,200
| +107% | +$7.04M | 0.01% | 949 |
|
|
2014
Q1 | $6.41M | Sell |
112,400
-42,000
| -27% | -$2.25M | 0.01% | 1517 |
|
|
2013
Q4 | $8.18M | Buy |
154,400
+144,800
| +1,508% | +$8.59M | 0.01% | 1406 |
|
|
2013
Q3 | $586K | Buy |
9,600
+1,400
| +17% | +$83.8K | ﹤0.01% | 3932 |
|
|
2013
Q2 | $497K | Buy |
+8,200
| New | +$488K | ﹤0.01% | 4200 |
|
Other funds holding DGX
VCM
VPM
EIG
Barclays's DGX Position: Q1 2026 in Review
Barclays increased its Quest Diagnostics (DGX) stake by 70% in Q1 2026, buying an estimated $45.1M and bringing the position to 565,470 shares worth $111M. The position accounts for 0.03% of the portfolio, ranked #460.
Barclays first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Barclays held 565,470 shares of Quest Diagnostics worth $111M as of Q1 2026.
- Barclays bought 232,168 Quest Diagnostics shares in Q1 2026, an estimated $45.1M.
- Quest Diagnostics made up 0.03% of Barclays's portfolio in Q1 2026, its #460 holding.
- Barclays first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
- 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.